GlobeImmune, Inc. (GBIM)

OTCMKTS · Delayed Price · Currency is USD
0.0000
-0.0001 (-99.00%)
At close: Feb 13, 2026
0.00%
Market Cap 6.00
Revenue (ttm) 6.21M
Net Income (ttm) -2.07M
Shares Out 5.75M
EPS (ttm) -0.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 190
Average Volume 4,030
Open 0.0000
Previous Close 0.0001
Day's Range 0.0000 - 0.0000
52-Week Range 0.0000 - 0.0005
Beta -329.26
RSI 40.98
Earnings Date n/a

About GlobeImmune

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platforms. The company’s product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medu... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1995
Employees 3
Stock Exchange OTCMKTS
Ticker Symbol GBIM
Full Company Profile

Financial Performance

In 2015, GlobeImmune's revenue was $6.46 million, an increase of 8.24% compared to the previous year's $5.97 million. Losses were -$2.77 million, -88.19% less than in 2014.

Financial Statements

News

There is no news available yet.